Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
10
AKAN Quote, Financials, Valuation and Earnings
Last price:
$0.50
Seasonality move
:
-21.9%
Day range:
$0.49 - $0.54
52-week range:
$0.49 - $9.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.93x
P/B ratio:
0.71x
Volume:
2.3M
Avg. volume:
5.7M
1-year change:
-89.57%
Market cap:
$362.5K
Revenue:
$836.7K
EPS (TTM):
-$461.78
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AKAN
Akanda Corp.
|
-- | -- | -- | -- | -- |
|
ABTI
Alterola Biotech, Inc.
|
-- | -- | -- | -- | -- |
|
ADTX
Aditxt, Inc.
|
-- | -- | -- | -- | -- |
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$167.4M | $0.37 | 60.47% | -62.86% | $54.71 |
|
LIVN
LivaNova Plc
|
$342.3M | $0.92 | 9.77% | -20.8% | $70.64 |
|
NVCR
NovoCure Ltd.
|
$158.9M | -$0.42 | 4.75% | -35.35% | $24.79 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AKAN
Akanda Corp.
|
$0.50 | -- | $362.5K | -- | $0.00 | 0% | 0.93x |
|
ABTI
Alterola Biotech, Inc.
|
$0.0065 | -- | $9.5M | -- | $0.00 | 0% | -- |
|
ADTX
Aditxt, Inc.
|
$1.14 | -- | $571.6K | -- | $0.00 | 0% | 37.06x |
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$42.49 | $54.71 | $3.2B | 94.78x | $0.00 | 0% | 5.44x |
|
LIVN
LivaNova Plc
|
$63.08 | $70.64 | $3.4B | 38.16x | $0.00 | 0% | 2.56x |
|
NVCR
NovoCure Ltd.
|
$13.44 | $24.79 | $1.5B | -- | $0.00 | 0% | 2.31x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AKAN
Akanda Corp.
|
7.2% | 1.308 | 5.92% | 1.17x |
|
ABTI
Alterola Biotech, Inc.
|
-- | 627.332 | -- | -- |
|
ADTX
Aditxt, Inc.
|
692.23% | 3.517 | 345.85% | 0.01x |
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
1.78% | -0.243 | 0.33% | 3.27x |
|
LIVN
LivaNova Plc
|
29.6% | 1.882 | 17.01% | 1.05x |
|
NVCR
NovoCure Ltd.
|
70.04% | -1.015 | 55.15% | 1.44x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AKAN
Akanda Corp.
|
-- | -- | -276.52% | -389.63% | -- | -- |
|
ABTI
Alterola Biotech, Inc.
|
-- | -$477.2K | -- | -- | -- | -$920.6K |
|
ADTX
Aditxt, Inc.
|
-$67.5K | -$3.1M | -319.72% | -681.25% | -448657.14% | -$2.3M |
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$97.3M | $24M | 7.44% | 7.6% | 13.28% | $33M |
|
LIVN
LivaNova Plc
|
$244.9M | $56.6M | -12.15% | -18.29% | 15.83% | $62.2M |
|
NVCR
NovoCure Ltd.
|
$122.5M | -$36M | -16.67% | -50.08% | -21.54% | $14.9M |
Akanda Corp. vs. Competitors
-
Which has Higher Returns AKAN or ABTI?
Alterola Biotech, Inc. has a net margin of -- compared to Akanda Corp.'s net margin of --. Akanda Corp.'s return on equity of -389.63% beat Alterola Biotech, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AKANAkanda Corp.-- -- $4.9M ABTIAlterola Biotech, Inc.-- -$0.00 -- -
What do Analysts Say About AKAN or ABTI?
Akanda Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Alterola Biotech, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Akanda Corp. has higher upside potential than Alterola Biotech, Inc., analysts believe Akanda Corp. is more attractive than Alterola Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AKANAkanda Corp.0 0 0 ABTIAlterola Biotech, Inc.0 0 0 -
Is AKAN or ABTI More Risky?
Akanda Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alterola Biotech, Inc. has a beta of 67.855, suggesting its more volatile than the S&P 500 by 6685.538%.
-
Which is a Better Dividend Stock AKAN or ABTI?
Akanda Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alterola Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akanda Corp. pays -- of its earnings as a dividend. Alterola Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKAN or ABTI?
Akanda Corp. quarterly revenues are --, which are smaller than Alterola Biotech, Inc. quarterly revenues of --. Akanda Corp.'s net income of -- is lower than Alterola Biotech, Inc.'s net income of -$691.8K. Notably, Akanda Corp.'s price-to-earnings ratio is -- while Alterola Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akanda Corp. is 0.93x versus -- for Alterola Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKANAkanda Corp.0.93x -- -- -- ABTIAlterola Biotech, Inc.-- -- -- -$691.8K
-
Which has Higher Returns AKAN or ADTX?
Aditxt, Inc. has a net margin of -- compared to Akanda Corp.'s net margin of -3458242.86%. Akanda Corp.'s return on equity of -389.63% beat Aditxt, Inc.'s return on equity of -681.25%.
Company Gross Margin Earnings Per Share Invested Capital AKANAkanda Corp.-- -- $4.9M ADTXAditxt, Inc.-9642.86% -$548.81 $179.3K -
What do Analysts Say About AKAN or ADTX?
Akanda Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Aditxt, Inc. has an analysts' consensus of -- which suggests that it could grow by 897058723.53%. Given that Aditxt, Inc. has higher upside potential than Akanda Corp., analysts believe Aditxt, Inc. is more attractive than Akanda Corp..
Company Buy Ratings Hold Ratings Sell Ratings AKANAkanda Corp.0 0 0 ADTXAditxt, Inc.0 0 0 -
Is AKAN or ADTX More Risky?
Akanda Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Aditxt, Inc. has a beta of 1.264, suggesting its more volatile than the S&P 500 by 26.35%.
-
Which is a Better Dividend Stock AKAN or ADTX?
Akanda Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aditxt, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akanda Corp. pays -- of its earnings as a dividend. Aditxt, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKAN or ADTX?
Akanda Corp. quarterly revenues are --, which are smaller than Aditxt, Inc. quarterly revenues of $700. Akanda Corp.'s net income of -- is lower than Aditxt, Inc.'s net income of -$24.2M. Notably, Akanda Corp.'s price-to-earnings ratio is -- while Aditxt, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akanda Corp. is 0.93x versus 37.06x for Aditxt, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKANAkanda Corp.0.93x -- -- -- ADTXAditxt, Inc.37.06x -- $700 -$24.2M
-
Which has Higher Returns AKAN or KNSA?
Kiniksa Pharmaceuticals International Plc has a net margin of -- compared to Akanda Corp.'s net margin of 10.19%. Akanda Corp.'s return on equity of -389.63% beat Kiniksa Pharmaceuticals International Plc's return on equity of 7.6%.
Company Gross Margin Earnings Per Share Invested Capital AKANAkanda Corp.-- -- $4.9M KNSAKiniksa Pharmaceuticals International Plc53.78% $0.23 $545.1M -
What do Analysts Say About AKAN or KNSA?
Akanda Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Kiniksa Pharmaceuticals International Plc has an analysts' consensus of $54.71 which suggests that it could grow by 28.77%. Given that Kiniksa Pharmaceuticals International Plc has higher upside potential than Akanda Corp., analysts believe Kiniksa Pharmaceuticals International Plc is more attractive than Akanda Corp..
Company Buy Ratings Hold Ratings Sell Ratings AKANAkanda Corp.0 0 0 KNSAKiniksa Pharmaceuticals International Plc6 0 0 -
Is AKAN or KNSA More Risky?
Akanda Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kiniksa Pharmaceuticals International Plc has a beta of 0.017, suggesting its less volatile than the S&P 500 by 98.312%.
-
Which is a Better Dividend Stock AKAN or KNSA?
Akanda Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kiniksa Pharmaceuticals International Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akanda Corp. pays -- of its earnings as a dividend. Kiniksa Pharmaceuticals International Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKAN or KNSA?
Akanda Corp. quarterly revenues are --, which are smaller than Kiniksa Pharmaceuticals International Plc quarterly revenues of $180.9M. Akanda Corp.'s net income of -- is lower than Kiniksa Pharmaceuticals International Plc's net income of $18.4M. Notably, Akanda Corp.'s price-to-earnings ratio is -- while Kiniksa Pharmaceuticals International Plc's PE ratio is 94.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akanda Corp. is 0.93x versus 5.44x for Kiniksa Pharmaceuticals International Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKANAkanda Corp.0.93x -- -- -- KNSAKiniksa Pharmaceuticals International Plc5.44x 94.78x $180.9M $18.4M
-
Which has Higher Returns AKAN or LIVN?
LivaNova Plc has a net margin of -- compared to Akanda Corp.'s net margin of 7.49%. Akanda Corp.'s return on equity of -389.63% beat LivaNova Plc's return on equity of -18.29%.
Company Gross Margin Earnings Per Share Invested Capital AKANAkanda Corp.-- -- $4.9M LIVNLivaNova Plc68.44% $0.49 $1.6B -
What do Analysts Say About AKAN or LIVN?
Akanda Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand LivaNova Plc has an analysts' consensus of $70.64 which suggests that it could grow by 11.98%. Given that LivaNova Plc has higher upside potential than Akanda Corp., analysts believe LivaNova Plc is more attractive than Akanda Corp..
Company Buy Ratings Hold Ratings Sell Ratings AKANAkanda Corp.0 0 0 LIVNLivaNova Plc6 2 0 -
Is AKAN or LIVN More Risky?
Akanda Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LivaNova Plc has a beta of 1.020, suggesting its more volatile than the S&P 500 by 2.023%.
-
Which is a Better Dividend Stock AKAN or LIVN?
Akanda Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LivaNova Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akanda Corp. pays -- of its earnings as a dividend. LivaNova Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKAN or LIVN?
Akanda Corp. quarterly revenues are --, which are smaller than LivaNova Plc quarterly revenues of $357.8M. Akanda Corp.'s net income of -- is lower than LivaNova Plc's net income of $26.8M. Notably, Akanda Corp.'s price-to-earnings ratio is -- while LivaNova Plc's PE ratio is 38.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akanda Corp. is 0.93x versus 2.56x for LivaNova Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKANAkanda Corp.0.93x -- -- -- LIVNLivaNova Plc2.56x 38.16x $357.8M $26.8M
-
Which has Higher Returns AKAN or NVCR?
NovoCure Ltd. has a net margin of -- compared to Akanda Corp.'s net margin of -22.29%. Akanda Corp.'s return on equity of -389.63% beat NovoCure Ltd.'s return on equity of -50.08%.
Company Gross Margin Earnings Per Share Invested Capital AKANAkanda Corp.-- -- $4.9M NVCRNovoCure Ltd.73.25% -$0.33 $1.1B -
What do Analysts Say About AKAN or NVCR?
Akanda Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand NovoCure Ltd. has an analysts' consensus of $24.79 which suggests that it could grow by 84.42%. Given that NovoCure Ltd. has higher upside potential than Akanda Corp., analysts believe NovoCure Ltd. is more attractive than Akanda Corp..
Company Buy Ratings Hold Ratings Sell Ratings AKANAkanda Corp.0 0 0 NVCRNovoCure Ltd.4 2 0 -
Is AKAN or NVCR More Risky?
Akanda Corp. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovoCure Ltd. has a beta of 0.825, suggesting its less volatile than the S&P 500 by 17.463%.
-
Which is a Better Dividend Stock AKAN or NVCR?
Akanda Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovoCure Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akanda Corp. pays -- of its earnings as a dividend. NovoCure Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AKAN or NVCR?
Akanda Corp. quarterly revenues are --, which are smaller than NovoCure Ltd. quarterly revenues of $167.2M. Akanda Corp.'s net income of -- is lower than NovoCure Ltd.'s net income of -$37.3M. Notably, Akanda Corp.'s price-to-earnings ratio is -- while NovoCure Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akanda Corp. is 0.93x versus 2.31x for NovoCure Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AKANAkanda Corp.0.93x -- -- -- NVCRNovoCure Ltd.2.31x -- $167.2M -$37.3M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
